This article discusses the perioperative management of antithrombotic therapy and is part of
the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th …

The Covid-19 pandemic has introduced an array of organspecific and systemic phenotypes-
some previously observed in viral infections, including severe acute respiratory syndrome …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

Background Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine
diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet …

Background The use of warfarin reduces the rate of ischemic stroke in patients with atrial
fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor …

Background It is uncertain whether bridging anticoagulation is necessary for patients with
atrial fibrillation who need an interruption in warfarin treatment for an elective operation or …

Aims Patients with non-valvular atrial fibrillation (AF) and renal insufficiency are at increased
risk for ischaemic stroke and bleeding during anticoagulation. Rivaroxaban, an oral, direct …

Background Variation in and irreversibility of platelet inhibition with clopidogrel has led to
controversy about its optimum dose and timing of administration in patients with acute …

Background Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an
intravenous blocker of the adenosine diphosphate receptor P2Y12. This agent might have a …

Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute
coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death …